Spotlight on Antibodies | Episode 15 | March 1 - 31, 2026

Spotlight on Antibodies is a podcast from ⁠Biointron⁠, where we bring you the latest antibody industry trends. This month in March, we'll highlight antibody allostery, trends in developability, and anti-IgE therapeutics. 

Find us on Spotify, Apple Podcasts, Amazon Music, or anywhere you get your podcasts: https://creators.spotify.com/pod/profile/biointron/

References:

1. https://www.sciencedirect.com/science/article/abs/pii/S0734975024001769

2. https://www.tandfonline.com/doi/full/10.1080/19420862.2017.1367074#abstract

3. https://www.mdpi.com/2304-8158/14/8/1360

4. https://www.sciencedirect.com/science/article/pii/S002228362500381X

5. https://www.nature.com/articles/s41467-025-65666-3

6. https://www.tandfonline.com/doi/full/10.1080/19420862.2023.2185924#abstract

7. https://www.fiercebiotech.com/sponsored/why-early-developability-assessment-strategic-necessity-modern-antibody-discovery

8. https://www.tandfonline.com/doi/full/10.1080/19420862.2025.2562999

9. https://www.tandfonline.com/doi/full/10.1080/19420862.2025.2593055%4010.1080/tfocoll.2023.0.issue-biologics-developability

10. https://www.tandfonline.com/doi/full/10.1080/19420862.2026.2627669

11. https://www.frontiersin.org/journals/allergy/articles/10.3389/falgy.2026.1759921/full

12. https://www.biospace.com/press-releases/poplar-therapeutics-closes-45-million-series-a-extension-to-advance-development-of-lead-program-phb-050-a-new-class-of-anti-ige-therapy-for-multiple-atopic-conditions

13. https://excellergy.com/excellergy-to-be-acquired-by-novartis-for-up-to-usd-2-billion-to-advance-potentially-first-in-class-trifunctional-effector-cell-response-inhibitors/